Skip to main content
  • Growth In The Pharmaceuticals Market

    The global pharma market was worth $934.8 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%, a report from The Business Research Company shows. This is an accelerated pace compared to 5.2% for the years before 2017, but is slower than the other two large healthcare segments, medical equipment and healthcare services. Healthcare as a whole is growing at over 7% year on year.

  • Tech Integrated healthcare showing way forward

    With the introduction of Health2.0 in the mid-2000s and the germination of digital healthcare startups, the sector has undergone new milestones in last 5 years. About 90 percent of the startups evaluated in 2015 were working on preventive healthcare and monitoring solutions, revealed an InnAccel’s report.

  • Indian Patent act need revisions, requests Indian and Foreign pharmaceutical associations

    Indian and foreign pharmaceutical associations need amendment in section 146 of Indian patent act 1970 and form 27 for making Indian patenting system more efficient and it will eliminate vague and unnecessary annual working statement disclosures. Indian patent office has invited responses from stake holders and many pharmaceutical industries and association responded in this regards.

  • Next stop for Indian pharma companies should be Japan

    Japan continues to be one of the largest pharmaceutical markets in the globe only behind US and China. The country of 12-13 crores population and have greatest potential in pharmaceutical despite difficult demographic landscape. Life expectancy of Japanese population is higher in the world which is almost 80 years for male and 87 years for female. Older people need more medicine and this is the fundamental of pharmaceutical industry in the Japan.

  • FIRST FDA APPROVED DIGITAL MEDICINE – BRIEF NOTE

    ABOUT AUTHOR
    Rajesh S Vagh
    PharmaTutor Edu Labs,
    Surat, Gujarat, India
    rajesh@pharmatutor.org

    Last year in November, FDA had approved first DIGITAL MEDICINE, ABILIFY MYCITE which is a drug-device combination product comprised of Otsuka's oral aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor. In simple word, it is an aripiprazole tablet with sensor. It is indicated in adults for the treatment of schizophrenia, bipolar I disorder,  acute treatment of manic and mixed episodes as monotherapy and as adjunct to lithium or valproate, maintenance treatment as monotherapy and as adjunct to lithium or valproate and  adjunctive treatment of major depressive disorder.

  • KNOW ALL ABOUT THE E-PHARMACIES IN INDIA

    Today we live in a digital era where everything is available at your doorstep on just a finger click. Whether it is grocery items, food stuffs or medicine, you can order it online getting it delivered in a meanwhile of time. Initiative of Indian Government i.e. Digital India has opened a new ray of hope to E-commerce industry in India making people specially from Tier 2 and 3 cities become more inclined to learn and use of these applications of online shopping.

  • RETHINKING PACKAGING WITH R&D

    ABOUT AUTHOR
    Soumyanath Mishra
    Head & DGM, Packaging Development-F&D
    Mankind Research Centre
    soumyanath.mishra@mankindpharma.com

    Packaging is an important component in the development of various drug formulations in pharmaceutical industry. Packaging of pharmaceutical dosage forms has a close relationship between a pharmaceutical preparation and its package which is a major concern to the drug stability and safety. The selection of Packaging material is made on the basis of its efficacy and performance characteristics in preserving the quality, potency and safety of the pharmaceutical products. The stability testing of pharmaceutical products and compatibility testing of packaging materials is an integral part of R&D in pharmaceutical industry. The stability of a drug in solid and liquid dosage forms depends on the efficacy of the packaging materials to protect the drug from chemical degradation and changes in physical characteristics such as appearance, hardness, friability, dissolution, disintegration, weight variation, moisture contents and mechanical durability.

  • Cardiac Stent : Current market scenario and further price cut

    Indian Price regulator, NPPA has again reduced Cardiac stent prices after they price capped for around 85% in last year February 2017. Before price capped, bare metal stents (BMS) were used to be sold for Rs45,000 and drug-eluting stents (DES) for Rs1.2 lakhs. Well, in Feb 2017 their prices are reduced to 7400 and 30180, respectively. And obviously, companies dealing with stents were baffled and left with no clue. This article will discuss the market scenario in India after price cap up to recent time. The broad discussion is going on whether to include DES in speacial category of stent and allow manufacturers to drive more prices from it.

  • NEXUS BETWEEN MEDICAL HEALTHCARE PROFESSIONALS AND PHARMACEUTICAL COMPANIES : BOON OR BANE FOR PATIENTS

    { DOWNLOAD AS PDF }

    ABOUT AUTHORS
    BALVINDER SINGH*1, PAWAN JALWAL 1, VIKASH KUMAR RUHIL 2
    1Shri Baba Mastnath Institute of Pharmaceutical Sciences & Research,
    Baba Mastnath University, Asthal Bohar, Rohtak, Haryana, India
    2P.D.M. College of Pharmacy, P.D.M. University, Bahadurgarh, Haryana, India

    *balvindersinghpharmaco@gmail.com

    ABSTRACT
    What started as imparting education to medical healthcare professionals, regarding pharmaceutical products by various pharmaceutical companies, has now become a grave, giant problem in the category of bribery and to be more precise, corruption in this 21st century. Now detailing of pharmaceutical company product has included giving free physician’s sample packs, prescription pads, pen and includes an entire range of latest electronic gazettes of mobile phones, laptops, tablets, AC, Refrigerator, LED TV, sponsoring a conference, refreshment to all expenses like return air ticket with free boarding and lodging in national or international tourist spot or hilly area. The real problem is that nothing comes free; all these expenses will add to cost of medicines and medical fraternity will heed least to quality of medicine. Now the market is flooded with abundant, spurious, sub-standard medicines; as pharmaceutical companies have the confidence of selling these products by shelling huge, attractive offers/gifts to some of greedy doctors, who fall prey to their lucrative offers. In this article, the aim is to probe this association or rather; we can call nexus between the medical healthcare professionals and various pharmaceutical companies. Various aspects are covered in this article, like….How this association works? What is the modus operandi and rationale of this association? Various angles of this association; from medical healthcare professionals, medical councils, pharmaceutical companies and society point of views are covered.

  • BANKRUPTCY IN PHARMACEUTICALS

    ABOUT AUTHORS
    Rajesh Vagh
    PharmaTutor Edu Labs
    Surat, Gujarat
    rajesh@pharmatutor.org

    Bankruptcy may be a new term or less familiar with most of you but it is of higher importance. Bankruptcy is a legal status of a person or other entity that cannot repay debts to creditors. We may consider it as a white-collar fraud. First let me clear that bankrupt can be defined as different act in various jurisdiction but generally  bankruptcy statutes involve concealment of assets, concealment or destruction of documents, conflicts of interest, fraudulent claims, false statements or declarations, and fee fixing or redistribution arrangements etc.  Bankruptcy fraud is a federal crime in the USA and India.

Subscribe to Pharmapedia

Search this website